The estimated Net Worth of Xiaomeng Tong is at least $17.1 Миллион dollars as of 5 June 2020. Xiaomeng Tong owns over 360,000 units of Viela Bio stock worth over $215,559 and over the last 5 years Xiaomeng sold VIE stock worth over $16,920,000.
Xiaomeng has made over 3 trades of the Viela Bio stock since 2019, according to the Form 4 filled with the SEC. Most recently Xiaomeng sold 360,000 units of VIE stock worth $16,920,000 on 5 June 2020.
The largest trade Xiaomeng's ever made was selling 360,000 units of Viela Bio stock on 5 June 2020 worth over $16,920,000. On average, Xiaomeng trades about 232,030 units every 81 days since 2019. As of 5 June 2020 Xiaomeng still owns at least 8,622,353 units of Viela Bio stock.
You can see the complete history of Xiaomeng Tong stock trades at the bottom of the page.
Xiaomeng's mailing address filed with the SEC is C/O BOYU CAPITAL ADVISORY CO. LTD, SUITE, 1518, TWO PACIFIC PLACE, 88 QUEENSWAY, HONG KONG, , .
Over the last 5 years, insiders at Viela Bio have traded over $58,712,400 worth of Viela Bio stock and bought 1,261,091 units worth $24,062,867 . The most active insiders traders include Andreas Wicki, Xiaomeng Tong и Plc Astra Zeneca Uk Ltd Ast.... On average, Viela Bio executives and independent directors trade stock every 41 days with the average trade being worth of $6,348. The most recent stock trade was executed by Aaron Ren on 18 November 2020, trading 2,000 units of VIE stock currently worth $5,680.
Viela Bio, Inc., a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company's lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. It is also developing VIB4920 for kidney transplantation rejection and sjögren's syndrome; and VIB7734 for cutaneous lupus erythematosus. Viela Bio, Inc. has a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases in Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, the Philippines, Singapore, and Taiwan. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.
Viela Bio executives and other stock owners filed with the SEC include: